NEW YORK (GenomeWeb News) – Invitrogen will use BioMicro Systems’ microarray user interface hybridization system with its new NCode miRNA profiling platform, the companies said last week.
 
The companies will co-market BioMicro’s system, called MAUI, with the NCode arrays. 
 
Invitrogen said “preliminary data” shows that using the MAUI system with the NCode arrays results in a 10-fold gain in sensitivity over manual hybridization.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.